COVID-19’s Early Financing Fallout

article image

Venture-backed medtech companies are taking a pounding from COVID-19, and while VCs initially are pausing investment as they scramble to manage their portfolios through the chaos, they should find buying opportunities, particularly among later-stage companies.

As late as early March, 2020 looked to be a banner year for medtech venture financing. Now, the sector, along with much of the rest of the world, has come to a screeching halt and is clumsily digging out of an unprecedented economic and health disaster.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: